Organogenesis (ORGO) to Release Earnings on Thursday

Organogenesis (NASDAQ:ORGO) is projected to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Organogenesis to post earnings of $0.21 per share and revenue of $172.6750 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 5:00 PM ET.

Organogenesis Price Performance

ORGO stock opened at $3.84 on Thursday. The firm has a market cap of $487.33 million, a P/E ratio of -32.00 and a beta of 1.46. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.88 and a current ratio of 3.32. Organogenesis has a 1 year low of $2.61 and a 1 year high of $7.08. The stock has a 50-day simple moving average of $4.41 and a 200-day simple moving average of $4.62.

Insider Buying and Selling

In other Organogenesis news, Director Glenn H. Nussdorf sold 200,000 shares of the firm’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $5.14, for a total transaction of $1,028,000.00. Following the completion of the transaction, the director directly owned 2,565,591 shares of the company’s stock, valued at $13,187,137.74. This trade represents a 7.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have sold 500,000 shares of company stock worth $2,620,120. Corporate insiders own 33.00% of the company’s stock.

Hedge Funds Weigh In On Organogenesis

Large investors have recently modified their holdings of the stock. Mercer Global Advisors Inc. ADV acquired a new position in Organogenesis in the fourth quarter worth about $57,000. XTX Topco Ltd bought a new position in Organogenesis during the 4th quarter worth approximately $79,000. Oxford Asset Management LLP acquired a new position in shares of Organogenesis in the 4th quarter worth approximately $66,000. Millennium Management LLC grew its position in shares of Organogenesis by 481.2% in the 4th quarter. Millennium Management LLC now owns 483,742 shares of the company’s stock worth $2,506,000 after acquiring an additional 400,514 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in shares of Organogenesis in the 4th quarter valued at approximately $1,357,000. Institutional investors own 49.57% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ORGO. BTIG Research reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Organogenesis in a research report on Friday, December 26th. Wall Street Zen upgraded shares of Organogenesis from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Organogenesis in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $8.00.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.